OTCMKTS:PUMD ProUroCare Medical (PUMD) Stock Price, News & Analysis $0.0001 0.00 (0.00%) As of 05/21/2026 09:30 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartBuy This Stock About ProUroCare Medical Stock (OTCMKTS:PUMD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ProUroCare Medical alerts:Sign Up Key Stats Today's Range$0.0001▼$0.000150-Day Range N/A52-Week Range$0.0001▼$0.0002Volume20,000 shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview ProUroCare Medical, Inc. is a development‐stage medical device company focused on advancing minimally invasive diagnostic and therapeutic solutions for urological conditions. The company’s research and development efforts center on technologies intended to address lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH) and pelvic floor disorders, including urinary incontinence. ProUroCare aims to improve patient outcomes by offering alternatives to traditional surgical and pharmaceutical approaches. ProUroCare’s product portfolio is currently in preclinical and early clinical stages, with the company working toward securing regulatory clearances in the United States. Its development strategy emphasizes collaborative partnerships with urology specialists, academic research centers and clinical sites to conduct feasibility studies and pivotal trials. By aligning with established healthcare institutions, ProUroCare seeks to generate robust clinical data and accelerate time to market for its lead device candidates. Headquartered in the United States, ProUroCare serves a primarily domestic patient base while evaluating opportunities to expand into select international markets in Europe and Asia. The company’s go‐to‐market plan includes building a direct sales force focused on urology centers of excellence and exploring distribution agreements to broaden reach. ProUroCare also maintains ongoing dialogues with reimbursement experts to ensure appropriate coverage and payment pathways for its future therapies. ProUroCare is led by a management team and board of directors with experience in medical device innovation, regulatory affairs and commercial operations. Drawing on decades of combined expertise in product development, quality systems and clinical research, the leadership team is tasked with steering the company through pivotal development milestones and positioning it for long-term growth in the urology market. Markets OTCMKTS:PUMDAI Generated. May Contain Errors. Read More Receive PUMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProUroCare Medical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PUMD Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com PUMD Stock Analysis - Frequently Asked Questions How have PUMD shares performed this year? ProUroCare Medical's stock was trading at $0.0002 at the beginning of the year. Since then, PUMD stock has decreased by 50.0% and is now trading at $0.0001. How do I buy shares of ProUroCare Medical? Shares of PUMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today5/22/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED INSTRUMENTS Sub-IndustryMedical Equipment Current SymbolOTCMKTS:PUMD CIK1222244 Webwww.prourocare.com Phone(952) 476-9093Fax952-843-7031Employees2Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta1.08 7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (OTCMKTS:PUMD) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersSystem failure: The strongest leverage for gold…$9 trillion in U.S. debt must be refinanced in 2026 - at current rates - while the largest foreign buyers of T...Golden Portfolio | SponsoredSMX Could Be One of the Most Interesting Small Caps Right NowSMX (Security Matters) is developing molecular-level markers that embed digital identities directly into plast...Smallcaps Daily | SponsoredNew wave of tech IPOs coming?Cerebras surged 68% on its first trading day, hitting a nearly $67 billion valuation - and investors are now a...Mode Mobile | SponsoredI had never heard of this 1888 accountAn investment account dating back to 1888 has quietly delivered average annual returns of 29% over the last 25...The Oxford Club | SponsoredMaybe the Greatest Strategy of the DecadeNate Bear, Lead Technical Tactician at Monument Traders Alliance, is going public with his highest-conviction ...Monument Traders Alliance | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredHow to Profit from Elon’s AI lab before it goes publicElon Musk's AI lab has partnered with the Department of Defense, Oracle, and Palantir - and he just filed conf...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProUroCare Medical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProUroCare Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.